

## **GUIDELINES FOR UTERINE ARTERY EMBOLISATION (UAE)**

### **UAE OVERVIEW**

- Prospective randomised studies such as EMMY (Volkers et al. 2008) and REST (Edwards et al. 2007) have proven the role of UAE in the treatment of symptomatic fibroids.
- UAE should be considered as one of the treatment options alongside surgical treatments, endometrial ablation, medical management and conservative measures (RCOG/RCR 2013).
- *Indication:*
  - Significant lifestyle-altering symptoms, specifically heavy menstrual bleeding, severe dysmenorrhoea or anaemia (level 1 evidence)
  - Further indication in fibroids causing pain or mass effect on bladder or bowel (level 3 evidence)
  - UAE can also be undertaken for control of symptoms from adenomyosis (Nijenhuis et al. 2015).
- *Contraindications:*
  - Viable pregnancy
  - Gynaecological malignancy
  - Active uterine infection
- *Outcomes:*
  - Technical success: 95-97% (REST & EMMY)
  - Clinical outcome: 92% satisfactory at 24 months (EMMY)
  - Secondary hysterectomy: 11% at 32 months (REST)

### **GYNAECOLOGICAL REVIEW**

- Review by gynaecologist in clinic, with aim to confirm diagnosis of fibroid, exclude viable pregnancy and exclude infective or malignant gynaecological pathology.
- Discussion of appropriate alternative treatments including hysterectomy, myomectomy and ablation therapies
- If patient is keen to be referred for consideration of UAE, gynaecology team to write clinic letter to interventional radiology department.
- Gynaecology team to request gadolinium enhanced MRI pelvis (fibroid protocol) at time of writing UAE referral letter.

### **INTERVENTIONAL RADIOLOGY REVIEW**

- Review in IR clinic
- Detailed discussion regarding procedure
- Review of MRI including anatomical suitability for embolisation
- Risks of embolisation reviewed including:

**Guidelines**

**GL-IR-003**

**GUIDELINES FOR UTERINE ARTERY EMBOLISATION (UAE)**

- Infection
- Hysterectomy
- Ovarian failure/early menopause
- Non-target embolisation
- Pain, including use of PCA
- Post embolisation syndrome
- PV discharge
- Future gynaecological D&C (particularly pedunculated intra-cavitary fibroids)
- Implications for future fertility
- Clinic letter to referring gynaecologist and GP (+/- patient if appropriate). Copy of letter to be filed with IR department.
- IR will fill in radiology request form if proceeding to UAE.

**PRE-PROCEDURE PLANNING**

- Consent by IR consultant
- Nursing pre-assessment, including explanation of PCA and theatre recovery
- Removal of IUCD pre-procedure by GP practice nurse. Patient to arrange.
- Appointment for first 10 days of woman's menstrual cycle.
- Bed booked on level 11
- Theatre recovery notified of date of procedure.

**DAY OF PROCEDURE**

- Patient arrived at IR suite at 0800
- Pregnancy test
- IV cannulation
- PCA education
- **Pre-procedure medication:**
  - **Gentamicin 160mg iv**
  - **Paracetamol 1g iv**
  - **Diclofenac 50mg PO (OR PR)**
  - **Oramorph 20mg PO**

**PROCEDURE SUMMARY**

- Generally right common femoral artery (CFA) access only, occasionally bilateral CFA access.
- Selective catheterisation of bilateral IIA and uterine arteries, with or without microcatheter use.
- Embolisation with particles – PVA or calibrated microspheres - usually in the 500-700micron range, but can be smaller or larger at discretion of operator.

**Guidelines**

**GL-IR-003**

**GUIDELINES FOR UTERINE ARTERY EMBOLISATION (UAE)**

- Arterial closure devices generally used.
- **Intraprocedural medication:**
  - **Fentanyl 25micrograms iv aliquots, titrated to manage pain**
  - **Ondasetron 4mg iv 6 hourly**
  - **Midazolam 1mg iv aliquots, if required**

**THEATRE RECOVERY**

- Initial recovery in theatre recovery suite, with IR nurse
- **Analgesia with PCA**, which continues on ward.
- Bed rest 4-6 hours.
- 15 minutes observations for first 2 hours, 30 minutes observations for subsequent 2 hours, routine observations thereafter.
- Observation of arterial access site for haematoma. If haematoma develops, contact IR for review.

**WARD CARE**

- Monitoring of PCA.
- Arterial access site should be checked for haematoma. If haematoma develops, direct manual compression for 15-20 minutes.
- Can have light dinner on evening of procedure.
- Aim to mobilise the following morning with cessation of PCA.
- IR review the following morning post procedure.
- Aim to discharge home the following morning/afternoon post procedure (after IR review) if pain controlled with oral analgesia.
- Patient must have passed urine pre discharge.
- **Discharge drugs (7 day supply) to be prescribed by gynaecology junior doctors:**
  - **Paracetamol 1g 6 hourly**
  - **Ibuprofen 400mcg 6 hourly OR Diclofenac 75mg 8 hourly**
  - **Dihydrocodeine 30mg 6 hourly**

**POST PROCEDURE**

- Interventional radiology will arrange follow up gadolinium enhanced MRI pelvis for 3-6 months.
- If post discharge concerns, particularly of infection, urgent gynaecological review and liaison with interventional radiology.

**FURTHER READING**

Edwards, Richard D, Jonathan G Moss, Mary Ann Lumsden, Olivia Wu, Lilian S Murray, Sara Twaddle, Gordon D Murray, and Committee of the Randomized

Author: Dr Bhaskar Ganai (consultant interventional radiologist)

Issue number: 1

Issue Date: January 2016

Review Date: January 2018

Location: Imaging Shared Drive – Nursing

Page 3 of 4

**Guidelines**

**GL-IR-003**

**GUIDELINES FOR UTERINE ARTERY EMBOLISATION (UAE)**

- Trial of Embolization versus Surgical Treatment for Fibroids. 2007. "Uterine-Artery Embolization Versus Surgery for Symptomatic Uterine Fibroids." *The New England Journal of Medicine* 356 (4): 360–70. doi:10.1056/NEJMoa062003.
- Volkers, Nicole A, Wouter J K Hehenkamp, Patrick Smit, Willem M Ankum, Jim A Reekers, and Erwin Birnie. 2008. "Economic Evaluation of Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Uterine Fibroids: Results From the Randomized EMMY Trial.." *JVIR* 19 (7): 1007–16–quiz1017. doi:10.1016/j.jvir.2008.03.001.
- Nijenhuis, R J, A J Smeets, M Morpurgo, P F Boekkooi, P J H M Reuwer, M Smink, W J van Rooij, and P N M Lohle. 2015. "Uterine Artery Embolisation for Symptomatic Adenomyosis with Polyzone F-Coated Hydrogel Microspheres: Three-Year Clinical Follow-Up Using UFS-QoL Questionnaire.." *CardioVascular and Interventional Radiology* 38 (1): 65–71. doi:10.1007/s00270-014-0878-1.
- RCOG/RCR. 2013. "Clinical Recommendations on the Use of Uterine Artery Embolisation (UAE) in the Management of Fibroids," December, 1–24.
- Gupta, JK, Sinha, A, Lumsden, MA, Hickey, M. 2014. "Uterine Artery Embolization for Symptomatic Uterine Fibroids (Review)." *Cochrane Database of Systematic Reviews (Online)*. Chichester, UK: Cochrane. doi:10.1002/14651858.CD005073.pub4.
- NICE. "Interventional procedure overview of uterine artery embolisation for fibroids"
- van Overhagen, H., & Reekers, J. A. (2015). Uterine Artery Embolization for Symptomatic Leiomyomata. *CardioVascular and Interventional Radiology*, 38(3), 536–542. <http://doi.org/10.1007/s00270-014-1031-x>